What is China's VBP program?

The Volume-Based Procurement (VBP) program is a Chinese initiative to lower medical device prices through bulk purchasing, pressuring company margins.

When will J&J report Q2 results?

No specific date has been announced, but the company typically reports in mid-July.

How have China pressures affected JNJ's past results?

In previous quarters, VBP negatively impacted MedTech sales in China, but the company partially offset this with growth in other markets.

J&J's MedTech Segment Faces Key Test in Q2 2026

Johnson & Johnson's (JNJ) MedTech segment is set to report Q2 2026 results, testing whether strength in cardiovascular, surgery, and vision can compensate for persistent China VBP pressures.

July 6, 2026

2 min read

Source: Zacks

Johnson & Johnson's (JNJ) MedTech segment is set to report Q2 2026 results, testing whether strength in cardiovascular, surgery, and vision can compensate for persistent China VBP pressures.

Key Segment Expectations

While official numbers are pending, analysts are focusing on:

Cardiovascular: Expected growth from new innovations.
Surgery: Benefiting from a post-pandemic procedure rebound.
Vision: Growth driven by corrective products.
China: Continued headwinds from the Volume-Based Procurement (VBP) program.

Highlights from the Report

According to Zacks, Q2 results will gauge how well these segments offset China challenges, as MedTech remains a key growth driver.

Guidance

No official guidance has been issued yet, but management is expected to emphasize geographic diversification to reduce China dependence.

Stock Impact

JNJ shares are trading near 52-week highs; strong MedTech results could push the stock higher.

What This Means for Investors

MedTech remains critical for J&J. Investors should watch the company's ability to sustain growth amid regulatory pressures in China.

Frequently Asked Questions

MedTech is J&J's medical devices and health technologies division, covering cardiovascular, surgery, and vision products.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.